The U.S. roadside drug testing market is anticipated to reach USD 1.62 billion by 2030 and is anticipated to expand at a CAGR of 4.71% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market for roadside drug testing in the U.S. is experiencing significant growth, driven by the increasing legalization of recreational cannabis and the rise in drug-impaired driving incidents. As states legalize marijuana, law enforcement agencies face new challenges in ensuring road safety. This has led to a surge in demand for advanced roadside drug testing devices that can quickly and accurately detect various substances.
Traditional methods like urine and blood tests are being supplemented by more efficient technologies, such as oral fluid testing, which is non-invasive and provides immediate results. One of the latest developments is the integration of artificial intelligence (AI) into these devices, enhancing their accuracy and reducing human error. Portable breathalyzers that can detect both alcohol and drugs are also becoming more prevalent. Additionally, there is ongoing research into devices that can measure impairment rather than just the presence of drugs, addressing the issue of varying tolerance levels among individuals.
Federal initiatives and funding are further bolstering this market, with the National Highway Traffic Safety Administration (NHTSA) and other agencies investing in the development of more sophisticated testing tools. As the U.S. continues to address the complexities of drug-impaired driving, the market for roadside drug testing is expected to expand, with innovations focusing on improving detection capabilities and ensuring the safety of all road users.
Request a free sample copy or view report summary: U.S. Roadside Drug Testing Market Report
The alcohol segment accounted for the largest revenue share in 2023. Alcohol testing remains dominant in the market due to the long-standing recognition of alcohol impairment as a significant safety concern, the presence of well-defined legal limits, and the widespread use of standardized devices like breathalyzers for accurate and reliable testing.
The breath segment captured the largest revenue share in 2023. Breath testing is the most commonly used method for detecting alcohol impairment because it is quick, non-invasive, and provides immediate results. Breathalyzers are portable, making them convenient for use by law enforcement officers during roadside checks.
The highway police segment held the largest revenue share in 2023. These officers are often the first responders at the scene of traffic stops, accidents, and roadside checks, where impaired driving is a significant concern.
Grand View Research has segmented the U.S. roadside drug testing market based on sample, drug, test location, and states:
U.S. Roadside Drug Outlook (Revenue, USD Million, 2018 - 2030)
Alcohol
Cannabis/Marijuana
Cocaine
Opioids
Amphetamine & Methamphetamine
LSD
Others
U.S. Roadside Sample Outlook (Revenue, USD Million, 2018 - 2030)
Saliva
Breath
Urine
Blood
U.S. Roadside Test Location Outlook (Revenue, USD Million, 2018 - 2030)
Highway Police
Drug Enforcement Agencies
U.S. Roadside States Outlook (Revenue, USD Million, 2018 - 2030)
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
List of Key Players in theU.S. Roadside Drug Testing Market
Drägerwerk AG & Co. KGaA
Abbott.
Intoximeters
Lifeloc Technologies, Inc.
Hound Labs, Inc.
Immunalysis Corporation
CMI Inc.
Alcohol Countermeasure Systems Corp.
AK GlobalTech Corp.
PAS Systems International, Inc.
"The quality of research they have done for us has been excellent..."